Amikacin

Amikin, Arikayce

Antibiotic • Aminoglycoside

Premium

NTINephrotoxic

Half-life

2-3 hours

Protein Binding

0-11%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Nephrotoxicity
Ototoxicity
Neuromuscular blockade

Clinical alerts

Boxed warning

3 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Mechanism of action

Binds to 30S ribosomal subunit; resistant to many aminoglycoside-modifying enzymes

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Febrile Neutropenia
·Mycobacterium Abscessus Pulmonary Disease
·Mycobacterium Abscessus Infection
·Non-Tuberculous Mycobacterial (NTM) Infections
·Non-Tuberculous Mycobacteria Pulmonary Disease

Monitoring

Therapeutic range: 1–5 mg/L; Cmax 20-35 mg/L, Cmin < 5 mg/L

Interactions

No curated interaction pairs are recorded for Amikacin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nephrotoxicity
Ototoxicity
Vestibular toxicity

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Published parameters · PMID:17356005

Half-life: 2-3 hours
Protein binding: 0-11%
Clearance: 4 L/h; critically ill adult patients
Volume of distribution: 20 L
Renally eliminated: 95%; Dose review in renal impairment
Model: 2-compartment

Pregnancy & lactation

Not recorded for Amikacin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Amikacin

Amikin, Arikayce

Antibiotic • Aminoglycoside

Premium

NTINephrotoxic

Half-life

2-3 hours

Protein Binding

0-11%

Metabolized By

N/A

External

Drugs.com

Boxed warning

Nephrotoxicity
Ototoxicity
Neuromuscular blockade

Clinical alerts

Boxed warning

3 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Mechanism of action

Binds to 30S ribosomal subunit; resistant to many aminoglycoside-modifying enzymes

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Febrile Neutropenia
·Mycobacterium Abscessus Pulmonary Disease
·Mycobacterium Abscessus Infection
·Non-Tuberculous Mycobacterial (NTM) Infections
·Non-Tuberculous Mycobacteria Pulmonary Disease

Monitoring

Therapeutic range: 1–5 mg/L; Cmax 20-35 mg/L, Cmin < 5 mg/L

Interactions

No curated interaction pairs are recorded for Amikacin. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Nephrotoxicity
Ototoxicity
Vestibular toxicity

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Pharmacokinetics

Published parameters · PMID:17356005

Half-life: 2-3 hours
Protein binding: 0-11%
Clearance: 4 L/h; critically ill adult patients
Volume of distribution: 20 L
Renally eliminated: 95%; Dose review in renal impairment
Model: 2-compartment

Pregnancy & lactation

Not recorded for Amikacin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Amikacin Drug Profile | PharmaGraphX